Lumito AB publishes Quarterly Report 1, 2025
First quarter 2025, January 1 to March 31 • Net sales amounted to TSEK 0 (17).• Result after taxes amounted to TSEK -11 803 (-7 113).• Earnings per share before and after dilution amounted to SEK -0,04 (-0,03).• Cash flow from operating activities after changes in working capital amounted to TSEK -6 784 (-7,178).• Cash […]
Lumito featured at AACR 2025
The AACR Annual Meeting (American Association for Cancer Research) is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. Lumito gained valuable visibility through a presentation by Professor Paul Waring at Akoya’s Spotlight Theatre, […]
Lumito launches new website – highlighting increasing objectivity in tissue analysis
Lumito, a leading medical technology company focused on tissue analysis, is launching a new website today, centered around the core message: "Increasing objectivity in tissue analysis." "Our new website is a direct result of insights gathered from users and partners," says CEO Sanna Wallenborg. “There has been a clear need to better clarify and deepen […]
Lumito launches new image visualisation and analysis software in partnership with Katana Labs
We are excited to announce that the partnership between Lumito and Katana Labs has resulted in a customised analysis software solution tailored specifically for Lumito’s customers. Lumito and Katana Labs are launching an innovative, cloud-based image analysis and visualisation software. The new solution is specifically optimised for Lumito’s unique Scizys tissue imaging technology, which combines […]
Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery
We are excited to announce a collaboration between Lumito and Concept Life Sciences, a CRO (contract research organisation) based in UK, to enhance tissue analysis in drug discovery and development. This joint project will focus on evaluating and optimising Lumito’s innovative product Scizys, within Concept Life Sciences’ cutting-edge research service. This collaboration is more than […]
Lumito AB publishes year-end report 2024
Financial Overview Fourth quarter 2024, October 1 to December 31• Net sales amounted to TSEK 79 (0).• Result after taxes amounted to TSEK-15,476 (-5,777).• Earnings per share before and after dilution amounted to SEK -0.06 (-0.03).• Cash flow from operating activities after changes in working capital amounted to TSEK -6,213 (-5,480). Full Year 2024, 1 […]
Lumito and Truly Labs join forces to drive innovation and enhanced competitiveness in tissue analysis
We are excited to announce that Lumito and Truly Labs are joining forces in a strategic partnership to develop innovative, value-driven solutions that provide both companies with a competitive edge in tissue analysis. “We are truly happy about this partnership where we will work together to improve the quality and objectivity of tissue analysis. Combining […]
Lumito focus on the accelerated commercialisation of SCIZYS and are initiating a cost-reduction programme
Lumitos focus is commercialisation of SCIZYS and to ensure market introduction. The company will enter into a new loan agreement of 12,5 MSEK, which was announced in a separate press release, and at the same time initiate a cost reduction program. The cost savings are calculated to be 14 MSEK at a minimum annually and […]
Lumito refinances loan of SEK 12.5 million
The board of directors of Lumito AB ("Lumito" or the "Company") has decided to refinance parts of existing loan of SEK 20 million excluding interest from Fenja Capital II A/S (the “Existing Loan”) through a new loan of SEK 12.5 million (the “Loan”) from Fenja Capital II A/S (formerly Formue Nord Fokus A/S, the “Lender”). […]
Warrants of series TO6 were subscribed to approximately 94 percent and Lumito receives approximately SEK 12.6 million
Lumito AB (publ) ("Lumito" or the "Company") today announces the outcome of the exercise of warrants of series TO6, which were issued in connection to an issue and loan financing during the fourth quarter of 2023. In total, 32,206,770 warrants were exercised, corresponding to approximately 94 percent of the total number of outstanding warrants, for […]
